{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:17:02Z","timestamp":1783052222045,"version":"3.54.6"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jmoldx.2024.12.010","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T19:21:32Z","timestamp":1737660092000},"page":"282-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distribution of BCR::ABL1\u00a0Transcript Types and Response to Therapy in Pediatric Patients with Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"27","author":[{"given":"Esra","family":"Seiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne L.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Lukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sembill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-7271","authenticated-orcid":false,"given":"Axel","family":"Karow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-0394","authenticated-orcid":false,"given":"Manuela","family":"Krumbholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2024.12.010_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"International BCR-ABL Study Group: The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia: an international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib3","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94 Suppl 2","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.6026\/97320630010108","article-title":"Differences in structural elements of bcr-abl oncoprotein isoforms in chronic myelogenous leukemia","volume":"10","author":"Hai","year":"2014","journal-title":"Bioinformation"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5581\/1516-8484.20120072","article-title":"Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome","volume":"34","author":"de Carvalho","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib6","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"SAKK the German CML Study Group: Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib7","article-title":"Impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: a pairwise and bayesian network meta-analysis","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/genes15020232","article-title":"Frequencies of BCR::ABL1 transcripts in patients with chronic myeloid leukemia: a meta-analysis","volume":"15","author":"Romero-Morelos","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib9","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/cncr.31408","article-title":"The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib10","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.062","article-title":"Prognostic significance of transcript-type BCR - ABL1 in chronic myeloid leukemia","volume":"12","author":"Molica","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib11","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1111\/cas.15501","article-title":"Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia","volume":"113","author":"Su","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib12","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ejh.12597","article-title":"Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia","volume":"96","author":"Lin","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib15","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.18632\/oncotarget.27652","article-title":"Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib","volume":"11","author":"Genthon","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib16","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/jcm10143146","article-title":"Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib","volume":"10","author":"Marce","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"88","author":"Lee","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib19","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","article-title":"E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy","volume":"102","author":"Claudiani","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib20","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0609.2008.01170.x","article-title":"Correlation of BCR\/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia","volume":"82","author":"Adler","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3324\/haematol.2009.019224","article-title":"Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia","volume":"95","author":"Suttorp","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib23","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib24","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-022-01612-2","article-title":"Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy","volume":"36","author":"Salmon","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.13238","article-title":"Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay","volume":"103","author":"Kjaer","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ejh.13282","article-title":"\u201cVariant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay\u201d: is dPCR the key?","volume":"103","author":"Bernardi","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib27","first-page":"186","article-title":"An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders","volume":"8","author":"Cross","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","author":"Winn-Deen","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2141.2002.03508.x","article-title":"Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene","volume":"117","author":"Branford","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib31","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib34","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","article-title":"Evaluation of residual disease and TKI duration are critical predictive\u00a0factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients","volume":"25","author":"Nicolini","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib36","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bjh.15826","article-title":"Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study","volume":"185","author":"de Bruijn","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib37","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib39","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.3390\/cancers13164102","article-title":"Discontinuation of imatinib in children with chronic myeloid leukemia: a study from the international registry of childhood CML","volume":"13","author":"Millot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib40","first-page":"2555","article-title":"Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort","volume":"109","author":"Stiehler","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omtn.2017.05.003","article-title":"Gold nanoparticles for BCR-ABL1 gene silencing: improving tyrosine kinase inhibitor efficacy in chronic myeloid leukemia","volume":"7","author":"Vinhas","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib42","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/cncr.24468","article-title":"Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nrclinonc.2010.141","article-title":"Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination","volume":"7","author":"Bocchia","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib44","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/leu.2008.7","article-title":"A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease","volume":"22","author":"Maslak","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.12.010_bib45","first-page":"7.24.1","article-title":"Digital droplet PCR: CNV analysis and other applications","volume":"82","author":"Mazaika","year":"2014","journal-title":"Curr Protoc Hum Genet"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157825000170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157825000170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:06Z","timestamp":1775022186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157825000170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1525157825000170"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2024.12.010","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distribution of BCR::ABL1\u00a0Transcript Types and Response to Therapy in Pediatric Patients with Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}